ALDX
Aldeyra Therapeutics, Inc.
$2.27
-0.16 (-6.58%)
At close · Jul 2
Market Cap
$136.93M
Shares
60,321,068
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.27
Open$2.41
Day$2.25–2.53
52W$1.07–6.18
Avg vol 30d1.5M
Short int6.9M · 11.4% float · 6.3d
Short vol25%
Last earningsMay 4, 2023
DataJan 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−40% below
+
Price vs 50-day avg
+30% above
◦
RSI (14)
64 · neutral
+
MACD trend
positive
◦
52-week position
24% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $2 › 200d $4 — 200d above 50d
−
Institutional flow
-9% holders QoQ · +21 funds added
+
Insider flow
Net +$418.5K over 90 days · 0% sells
+
Short interest
11.38% of float · ▼ -13.6% MoM · 6.3 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
125 holders — mid 3-yr range
Fundamentals
Strong
+
EPS growth
+40% Y/Y
−
Free cash flow
$-33.3M
+
Balance sheet
net cash $54.7M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−40% below
Bearish
Price vs 50-day avg
+30% above
Bullish
RSI (14)
64 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
24% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +21 funds added
Insider flow
Accumulating
Net +$418.5K over 90 days · 0% sells
Short interest
Falling
11.38% of float · ▼ -13.6% MoM · 6.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
125 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 24%
52-wk high $6
vs 200-day avg -40%
vs 50-day avg +30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALDX
this stock
Aldeyra Therapeutics, Inc.
|
$136.93M | -56.2% | — | — | 11.4% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALDX | +26.1% | +22.0% | -45.7% | +6.6% | -56.2% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +24.7% | +23.3% | -53.7% | +6.8% | -65.4% |